Lyell Immunopharma, Inc.
Recent Filings
All 300 filings →| Form | Description | Date |
|---|---|---|
| 4 | — | Mar 16, 2026 |
| 3 | — | Mar 16, 2026 |
| S-8 | S-8 | Mar 12, 2026 |
| 10-K | 10-K | Mar 12, 2026 |
| 8-K | 8-K | Mar 12, 2026 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | Mar 9, 2026 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | Mar 9, 2026 |
| 8-K | 8-K | Mar 9, 2026 |
| 4 | — | Feb 12, 2026 |
| 4 | — | Feb 12, 2026 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Owns After | Date |
|---|---|---|---|---|---|
| Seely Lynn | President and CEO | Sale | 412 @ $16.11 | 67,159 | Nov 10, 2025 |
| Bulis Veronica Sanchez | VP, Corporate Controller | Sale | 239 @ $16.10 | 9,213 | Nov 10, 2025 |
| Lee Gary K. | Chief Scientific Officer | Sale | 138 @ $16.16 | 15,366 | Nov 10, 2025 |
| Hill Stephen J. | Chief Operating Officer | Sale | 95 @ $16.12 | 15,750 | Nov 10, 2025 |
| Hill Stephen J. | Chief Operating Officer | Award / Grant | 8,000 | 16,849 | Aug 21, 2025 |
| Lee Gary K. | Chief Scientific Officer | Award / Grant | 8,000 | 16,957 | Aug 21, 2025 |
| Seely Lynn | President and CEO | Sale | 7,257 @ $10.54 | 67,571 | Aug 20, 2025 |
| Newton Charles W. | Chief Financial Officer | Sale | 1,453 @ $10.54 | 15,306 | Aug 20, 2025 |
| Seely Lynn | President and CEO | Sale | 391 @ $10.53 | 35,234 | Aug 12, 2025 |
| Lee Gary K. | Chief Scientific Officer | Sale | 131 @ $10.53 | 9,093 | Aug 12, 2025 |